Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Has Consensus Target Price of $30.25

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has received an average recommendation of “Hold” from the eleven analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $30.25.

Several analysts have issued reports on the stock. HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a research note on Monday, July 27th. Alliance Global Partners lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a research report on Tuesday, July 28th. B. Riley Financial upgraded shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $5.00 to $21.00 in a research report on Monday, September 14th. Maxim Group cut shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Capricor Therapeutics in a report on Thursday.

Capricor Therapeutics Stock Performance

CAPR stock opened at $7.83 on Wednesday. The firm has a 50 day moving average of $7.76 and a 200-day moving average of $20.25. Capricor Therapeutics has a 12 month low of $2.96 and a 12 month high of $40.37. The firm has a market capitalization of $455.24 million, a P/E ratio of -3.20 and a beta of 0.61.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Sell-side analysts predict that Capricor Therapeutics will post -1.71 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in the business. SB Capital Management Inc bought a new stake in shares of Capricor Therapeutics during the 4th quarter valued at about $11,544,000. Bank of America Corp DE grew its holdings in shares of Capricor Therapeutics by 672.0% during the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after purchasing an additional 361,664 shares in the last quarter. Montanova Capital LLC increased its position in shares of Capricor Therapeutics by 7.2% in the second quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock worth $98,554,000 after purchasing an additional 274,184 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Capricor Therapeutics in the first quarter worth approximately $5,397,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Capricor Therapeutics in the second quarter worth approximately $3,895,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research is based on technologies intended to modulate inflammation, fibrosis and tissue damage, with an emphasis on rare and degenerative conditions.

Capricor’s lead investigational product is deramiocel, formerly known as CAP-1002. It is an allogeneic cell therapy derived from cardiosphere-derived cells and is being developed for Duchenne muscular dystrophy, a progressive genetic disorder that causes muscle degeneration.